Brugada syndrome (BrS) is primary electrical disorder characterized by ST segment elevation with right bundle branch block morphology in patients with apparent structurally normal hearts.[@b1] It predisposes affected individuals to ventricular tachycardia/fibrillation (VT/VF) and sudden cardiac death (SCD).[@b2] A number of studies have identified risk factors that are associated with a more malignant course of disease. These include male gender, syncope, a spontaneous type 1 ECG pattern, family history of SCD, family history of Brugada syndrome, loss-of-function mutations in the SCN5a gene, inducible VT/VF during programmed electrical stimulation. Of these risk factors, many studies have demonstrated that the presence of a spontaneous type 1 pattern is associated with a significantly higher risk of VT/VF or SCD, but other studies have demonstrated a lack of significant predictive value.

Three meta-analyses have addressed the prognostic value of a spontaneous type 1 Brugada pattern. Firstly, Letsas, *et al*.[@b3] examined its predictive value in six studies involving 2219 asymptomatic patients only, demonstrating a 3.6-fold increase in the risk of future arrhythmic events. Secondly, Wu, *et al*.[@b4] examined only prospective studies (*n* = 8) that included 1150 patients, demonstrating a 4-fold increase in the risk. Finally, Gehi, *et al*.[@b5] examined also only prospective studies (*n* = 3) in 935 patients, demonstrating a relative risk of 4.7. In this study, we performed an updated systematic review and meta-analysis, which includes the largest number of studies and patient numbers.

PubMed and Embase were searched for studies that investigated the association between a spontaneous type 1 Brugada pattern on the ECG and ventricular arrhythmias and SCD in Brugada syndrome. The following search terms were used for both databases: "Brugada syndrome spontaneous type 1". The search period was from the beginning of the database through to 30^th^ June 2017 without language restrictions. The following inclusion criteria were used: (1) the study was a case-control, prospective or retrospective cohort study in human subjects with a Brugada phenotype; and (2) data on the relationship between a type 1 pattern and adverse events (appropriate implantable cardioverter defibrillator shocks, VT/VF, and SCD) were reported.

A total of 139 and 10 entries were retrieved from PubMed and Embase, respectively. After reference trawling and excluding overlapping populations, a total of 6561 Brugada patients from 24 studies were included.[@b6]--[@b29] The mean age was 44 ± 16 years and 73% of the patients were male, with a mean follow-up of 50 ± 36 months. [Table 1](#jgc-14-10-639-t01){ref-type="table"} shows the baseline characteristics of these studies and the study populations. Quality analysis of the included studies by using the Newcastle-Ottawa Scale was shown in [Table 2](#jgc-14-10-639-t02){ref-type="table"}. The main finding of our meta-analysis is that the presence of a spontaneous type 1 pattern on the ECG confers 2.3 times the risk of ventricular arrhythmias or SCD in Brugada syndrome. There was a low level of heterogeneity (*I*^2^ = 42%) with significant publication bias (Kendall\'s tau = 0.37, *P* \< 0.05).

###### Characteristics of the studies included in this meta-analysis.

  Studies                            Study design   Sample size (*n*)   Age   Males                Endpoints                 Follow-up duration (months)   Univariate or multivariate                               Multivariate variables
  --------------------------------- -------------- ------------------- ----- ------- -------------------------------------- ----------------------------- ---------------------------- ---------------------------------------------------------------------------------
  Kitamura T, *et al*.[@b8]               R                304          30     169                   VT/VF                               91                            U                                                      \-
  Sieira J, *et al*.[@b9]                 P                400          41     233              SCD + ICD Shock                          81                            U                                                      \-
  Andorin A, *et al*.[@b13]               R                106          11     58           SCD + ICD Shock + VT/VF                      54                            M                                                  Age and ICD
  Casado-Arroyo R, *et al*.[@b11]         P                447          45     336          SCD + ICD Shock + VT/VF                      50                            U                                                      \-
  Kawazoe H, *et al*.[@b12]               R                143          46     140                     VF                                83                            U                                                      \-
  Rivard L, *et al*.[@b10]                R                105          46     83        aSCD + appropriate ICD shocks                   60                            M                                          Max Tp-e and QRS in lead 6
  Conte G, *et al*.[@b16]                 P                176          43     118           Appropriate ICD shocks                      84                            U                                                      \-
  Dores H, *et al*.[@b15]                 R                55           42     30            Appropriate ICD shocks                      74                            U                                                      \-
  Maury P, *et al*.[@b14]                 R                325          47     258        SCD + appropriate ICD shocks                   48                            M                Sp1 ST elevation, SCN5A mutation, family history of SCD, QRS duration, Max Tp-e
  Okamura H, *et al*.[@b17]               R                218          46     211        SCD + appropriate ICD shocks                   78                            M                                    Sp1, Syncope, inducibility of VF (PES+)
  Son MK, *et al*.[@b19]                  R                69           48     68     Appropriate/inappropriate ICD shocks               57                            M                         Age, presence of palpitations, sVT before implantation of ICD
  Tokioka K, *et al*.[@b18]               R                246          48     236            SCD + ICD Shock + VF                       45                            U                                                      \-
  Hiraoka M, *et al*.[@b20]               P                460          52     432                  SCD + VF                             43                            U                                                      \-
  Daoulah A, *et al*.[@b21]               R                25           32     25            Appropriate ICD shocks                      41                            NA                                                     \-
  Delise P, *et al*.[@b23]                P                320          43     258                  SCD + VF                             40                            M                                           Syncope, basal type 1 ECG
  Nishii N, *et al*.[@b22]                P                108          49     10            Appropriate ICD shocks                      72                            U                                                      \-
  Probst V, *et al*.[@b25]                R               1029          45     745        SCD + appropriate ICD shocks                   32                            M                   Symptoms at diagnosis (aSCD/asymptomatic/syncope), Sp1, age, gender, EPS
  Richter S, *et al*.[@b24]               P                186          43     115     aSCD + appropriate ICD shocks + VF                57                            U               
  Giustetto C, *et al*.[@b27]             P                166          42     138     aSCD + appropriate ICD shocks + VF                30                            U                                                      \-
  Kamakura S, *et al*.[@b26]              R                330          51     315                  SCD + VF                             49                            U                                                      \-
  Benito B, *et al*.[@b28]                P                384          46     272                  SCD + VF                             58                            M                     Gender, previous AF, symptoms at diagnosis (syncope, aSCD), Sp1, EPS
  Eckardt L, *et al*.[@b29]               R                212          45     152        Appropriate ICD shocks + VF                    40                            U                                                      \-
  Brugada J, *et al*.[@b6]                P                547          41     408                  SCD + VF                             24                            M                                     Gender, Sp1, syncope, EPS (inducible)
  Priori SG, *et al*.[@b7]                P                200          41     152               Cardiac arrest                          34                            U                                                      \-

AF: atrial fibrillation; aICD: appropriate implantable cardioverter defibrillator; aSCD: aborted sudden cardiac death; EPS: electrophysiological study; ICD: implantable cardioverter defibrillator; M: multivariate; NA: not available; P: prospective; R: retrospective; sVT: sustained ventricular tachycardia; U: univariate; VF: ventricular fibrillation.

###### NOS risk of bias scale for included cohort studies.

  Studies                            Selection   Outcome                                                          
  --------------------------------- ----------- --------- --- --- ----------------------------------- --- --- --- ---
  Priori SG, *et al*.[@b7]               1          0      1   0                   0                   1   1   1   5
  Brugada J, *et al*.[@b6]               1          0      1   1                   0                   1   1   1   6
  Benito B, *et al*.[@b28]               1          0      1   1                   0                   1   1   1   6
  Delise P, *et al*.[@b23]               1          0      1   1   2 (gender, family history of SCD)   1   1   1   8
  Probst V, *et al*.[@b25]               1          0      1   1                   0                   1   1   1   6
  Nishii N, *et al*.[@b22]               1          0      1   1                   0                   1   1   1   6
  Daoulah A, *et al*.[@b21]              1          0      1   0                   0                   1   1   1   5
  Hiraoka M, *et al*.[@b20]              1          0      1   1   2 (gender, family history of SCD)   1   1   1   8
  Son MK, *et al*.[@b19]                 1          0      1   0              1 (gender)               1   1   1   6
  Tokioka K, *et al*.[@b18]              1          0      1   0       1 (family history of SCD)       1   1   1   6
  Conte G, *et al*.[@b16]                1          0      1   1   2 (gender, family history of SCD)   1   1   1   8
  Dores H, *et al*.[@b15]                1          0      1   0   2 (gender, family history of SCD)   1   1   1   7
  Okamura H, *et al*.[@b17]              1          0      1   0   2 (gender, family history of SCD)   1   1   1   7
  Andorin A, *et al*.[@b13]              1          0      1   1   2 (gender, family history of SCD)   1   1   1   8
  Casado-Arroyo R, *et al*.[@b11]        1          0      1   1   2 (gender, family history of SCD)   1   1   1   8
  Kawazoe H, *et al*.[@b12]              1          0      1   0   2 (gender, family history of SCD)   1   1   1   7
  Rivard L, *et al*.[@b10]               1          0      1   1              1 (gender)               1   1   1   7
  Kitamura T, *et al*.[@b8]              1          0      1   0   2 (gender, family history of SCD)   1   1   1   7
  Sieira, *et al*.[@b9]                  1          0      1   1              1 (gender)               1   1   1   7

NOS: Newcastle-Ottawa scale; SCD: sudden cardiac death.

The ECG is a simple and non-invasive test that provides information on cardiac electrophysiological properties of the test subjects. A spontaneous Brugada pattern indicates the presence of both depolarization and repolarization abnormalities at baseline, which represent substrates for re-entrant arrhythmogenesis.[@b30]--[@b32] This is in contrast to the presence of a type 2 or type 3 Brugada pattern, which can be converted to a type 1 pattern using drug challenge.[@b33] In addition to this type 1 characteristic pattern, detailed analyses of conduction and repolarization intervals from the 12-lead ECG can aid risk stratification.[@b34]--[@b37] For example, a recent meta-analysis has demonstrated that prolonged T~peak~--T~end~ intervals, which represent a higher dispersion of repolarization, whilst another showed that fragmented QRS complex,[@b38] which indicates dispersion of conduction, are associated with higher risk of ventricular arrhythmias and sudden death in Brugada syndrome. Our meta-analysis shows patients with spontaneous type 1 Brugada pattern are at a high risk of adverse events. The ECG is a valuable tool that can aid clinicians to identify such high-risk individuals, who will require primary prevention by implantable cardioverter-defibrillator insertion.
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